{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:49:56Z","timestamp":1782870596022,"version":"3.54.5"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Abdom Radiol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Transurethral ultrasound ablation (TULSA) is an MRI-guided thermal therapy that enables focal or whole-gland ablation of prostate tissue using real-time MR thermometry and feedback control. It is an emerging treatment option for carefully selected patients with localized prostate cancer, particularly when preservation of urinary and sexual function is an important clinical priority. However, TULSA is not yet an established equivalent to radical prostatectomy or radiation therapy, because available clinical data on long-term oncologic control remain limited. Radiologists should therefore understand both its potential role and the limitations of the current evidence. Multiparametric MRI plays a central role throughout the TULSA workflow, including lesion localization, assessment of extraprostatic extension and seminal vesicle invasion, evaluation of critical periprostatic structures, and identification of calcifications that may interfere with ultrasound transmission. Immediately after treatment, contrast-enhanced MRI is used to assess the non-perfused ablation zone, whereas serial imaging demonstrates progressive volume reduction and tissue remodeling. Interpretation may be challenging because inflammation, vascular changes, coagulative necrosis, and anatomical distortion can mimic or obscure residual disease. This pictorial essay provides a practical review of patient selection, treatment planning, post-treatment assessment, and imaging pitfalls after TULSA, based on institutional experience with more than 100 cases.<\/jats:p>","DOI":"10.1007\/s00261-026-05642-7","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:22:44Z","timestamp":1782868964000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transurethral ultrasound ablation for prostate cancer: MRI-based pre-treatment planning and post-treatment assessment\u2014what the radiologist needs to know"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6621-9206","authenticated-orcid":false,"given":"Satoru","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayoshi","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Higashiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"5642_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"5642_CR2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.euo.2023.08.011","volume":"7","author":"R Hogenhout","year":"2024","unstructured":"Hogenhout R, Remmers S, van Slooten-Midderigh ME, de V, II, Roobol MJ, Group ERS (2024) From Screening to Mortality Reduction: An Overview of Empirical Data on the Patient Journey in European Randomized Study of Screening for Prostate Cancer Rotterdam After 21 Years of Follow-up and a Reflection on Quality of Life. Eur Urol Oncol 7:713\u2013720. https:\/\/doi.org\/10.1016\/j.euo.2023.08.011","journal-title":"Eur Urol Oncol"},{"key":"5642_CR3","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.eururo.2024.11.013","volume":"87","author":"EJ Schafer","year":"2025","unstructured":"Schafer EJ, Laversanne M, Sung H et al (2025) Recent Patterns and Trends in Global Prostate Cancer Incidence and Mortality: An Update. Eur Urol 87:302\u2013313. https:\/\/doi.org\/10.1016\/j.eururo.2024.11.013","journal-title":"Eur Urol"},{"key":"5642_CR4","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1001\/jama.2023.26491","volume":"331","author":"Hussein Al Al","year":"2024","unstructured":"Al Hussein Al Awamlh B, Wallis CJD, Penson DF et al (2024) Functional Outcomes After Localized Prostate Cancer Treatment. JAMA 331:302\u2013317. https:\/\/doi.org\/10.1001\/jama.2023.26491","journal-title":"JAMA"},{"key":"5642_CR5","volume-title":"EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer","author":"P Cornford","year":"2025","unstructured":"Cornford P, Tilki D, Bergh RCNvd et al (2025) EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer. EAU Guidelines Office, Arnhem, The Netherlands"},{"key":"5642_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.eururo.2018.01.001","volume":"74","author":"HG van der Poel","year":"2018","unstructured":"van der Poel HG, van den Bergh RCN, Briers E et al (2018) Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. Eur Urol 74:84\u201391. https:\/\/doi.org\/10.1016\/j.eururo.2018.01.001","journal-title":"Eur Urol"},{"key":"5642_CR7","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2015.12.029","volume":"70","author":"JL Chin","year":"2016","unstructured":"Chin JL, Billia M, Relle J et al (2016) Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Tissue in Patients with Localized Prostate Cancer: A Prospective Phase 1 Clinical Trial. Eur Urol 70:447\u2013455. https:\/\/doi.org\/10.1016\/j.eururo.2015.12.029","journal-title":"Eur Urol"},{"key":"5642_CR8","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1089\/end.2021.0866","volume":"36","author":"C Dora","year":"2022","unstructured":"Dora C, Clarke GM, Frey G, Sella D (2022) Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer: A Systematic Review. J Endourol 36:841\u2013854. https:\/\/doi.org\/10.1089\/end.2021.0866","journal-title":"J Endourol"},{"key":"5642_CR9","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1097\/JU.0000000000001362","volume":"205","author":"L Klotz","year":"2021","unstructured":"Klotz L, Pavlovich CP, Chin J et al (2021) Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Prostate Cancer. J Urol 205:769\u2013779. https:\/\/doi.org\/10.1097\/JU.0000000000001362","journal-title":"J Urol"},{"key":"5642_CR10","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1002\/bco2.175","volume":"3","author":"M Miura","year":"2022","unstructured":"Miura M, Takahashi S, Fukumoto M, Higashiyama H (2022) Initial experience of transurethral ultrasound ablation of the prostate in Asia. BJUI Compass 3:405\u2013407. https:\/\/doi.org\/10.1002\/bco2.175.","journal-title":"BJUI Compass"},{"key":"5642_CR11","doi-asserted-by":"publisher","unstructured":"Lumiani A, Samun D, Sroka R, Muschter R (2021) Single center retrospective analysis of fifty-two prostate cancer patients with customized MR-guided transurethral ultrasound ablation (TULSA). Urol Oncol 39:830 e9\u2013830 e16. https:\/\/doi.org\/10.1016\/j.urolonc.2021.04.022","DOI":"10.1016\/j.urolonc.2021.04.022"},{"key":"5642_CR12","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s00270-024-03696-y","volume":"47","author":"KFK Fung","year":"2024","unstructured":"Fung KFK, Cazzato RL, Tricard T et al (2024) MR-Guided Transurethral Ultrasound Ablation (TULSA)-An Emerging Minimally Invasive Treatment Option for Localised Prostate Cancer. Cardiovasc Intervent Radiol 47:689\u2013701. https:\/\/doi.org\/10.1007\/s00270-024-03696-y","journal-title":"Cardiovasc Intervent Radiol"},{"key":"5642_CR13","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/21681805.2020.1814857","volume":"54","author":"M Anttinen","year":"2020","unstructured":"Anttinen M, Makela P, Nurminen P et al (2020) Palliative MRI-guided transurethral ultrasound ablation for symptomatic locally advanced prostate cancer. Scand J Urol 54:481\u2013486. https:\/\/doi.org\/10.1080\/21681805.2020.1814857","journal-title":"Scand J Urol"},{"key":"5642_CR14","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12894-023-01306-6","volume":"23","author":"I Peters","year":"2023","unstructured":"Peters I, Hensen B, Glandorf J et al (2023) First experiences using transurethral ultrasound ablation (TULSA) as a promising focal approach to treat localized prostate cancer: a monocentric study. BMC Urol 23:142. https:\/\/doi.org\/10.1186\/s12894-023-01306-6","journal-title":"BMC Urol"},{"key":"5642_CR15","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1016\/j.jvir.2025.05.024","volume":"36","author":"T Tricard","year":"2025","unstructured":"Tricard T, Cazzato RL, Schroeder A et al (2025) Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer (MRI-TULSA): A Prospective Trial. J Vasc Interv Radiol 36:1401\u20131408. https:\/\/doi.org\/10.1016\/j.jvir.2025.05.024","journal-title":"J Vasc Interv Radiol"},{"key":"5642_CR16","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13244-023-01428-3","volume":"14","author":"A Guerra","year":"2023","unstructured":"Guerra A, Flor-de-Lima B, Freire G, Lopes A, Cassis J (2023) Radiologic-pathologic correlation of prostatic cancer extracapsular extension (ECE). Insights Imaging 14:88. https:\/\/doi.org\/10.1186\/s13244-023-01428-3","journal-title":"Insights Imaging"},{"key":"5642_CR17","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.eururo.2015.07.029","volume":"70","author":"M de Rooij","year":"2016","unstructured":"de Rooij M, Hamoen EH, Witjes JA, Barentsz JO, Rovers MM (2016) Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. Eur Urol 70:233\u2013245. https:\/\/doi.org\/10.1016\/j.eururo.2015.07.029","journal-title":"Eur Urol"},{"key":"5642_CR18","doi-asserted-by":"publisher","first-page":"109804","DOI":"10.1016\/j.ejrad.2021.109804","volume":"141","author":"I Caglic","year":"2021","unstructured":"Caglic I, Sushentsev N, Shah N, Warren AY, Lamb BW, Barrett T (2021) Comparison of biparametric versus multiparametric prostate MRI for the detection of extracapsular extension and seminal vesicle invasion in biopsy naive patients. Eur J Radiol 141:109804. https:\/\/doi.org\/10.1016\/j.ejrad.2021.109804","journal-title":"Eur J Radiol"},{"key":"5642_CR19","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/21681805.2019.1660707","volume":"53","author":"M Anttinen","year":"2019","unstructured":"Anttinen M, Makela P, Suomi V et al (2019) Feasibility of MRI-guided transurethral ultrasound for lesion-targeted ablation of prostate cancer. Scand J Urol 53:295\u2013302. https:\/\/doi.org\/10.1080\/21681805.2019.1660707","journal-title":"Scand J Urol"},{"key":"5642_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.eururo.2009.11.009","volume":"57","author":"J Walz","year":"2010","unstructured":"Walz J, Burnett AL, Costello AJ et al (2010) A critical analysis of the current knowledge of surgical anatomy related to optimization of cancer control and preservation of continence and erection in candidates for radical prostatectomy. Eur Urol 57:179\u2013192. https:\/\/doi.org\/10.1016\/j.eururo.2009.11.009","journal-title":"Eur Urol"},{"key":"5642_CR21","doi-asserted-by":"publisher","first-page":"2003","DOI":"10.1148\/rg.2019190064","volume":"39","author":"J Lakhoo","year":"2019","unstructured":"Lakhoo J, Khatri G, Elsayed RF et al (2019) MRI of the Male Pelvic Floor. Radiographics 39:2003\u20132022. https:\/\/doi.org\/10.1148\/rg.2019190064","journal-title":"Radiographics"},{"key":"5642_CR22","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1148\/radiographics.21.5.g01se121169","volume":"21","author":"J Ryu","year":"2001","unstructured":"Ryu J, Kim B (2001) MR imaging of the male and female urethra. Radiographics 21:1169\u20131185. https:\/\/doi.org\/10.1148\/radiographics.21.5.g01se121169","journal-title":"Radiographics"},{"key":"5642_CR23","doi-asserted-by":"publisher","first-page":"e92995","DOI":"10.7759\/cureus.92995","volume":"17","author":"K Johnson","year":"2025","unstructured":"Johnson K, Mehan R (2025) Removal of Prostate Calcifications Prior to TULSA-PRO With the Aid of Real-Time Ultrasound Imaging: Our Technique and Experience. Cureus 17:e92995. https:\/\/doi.org\/10.7759\/cureus.92995","journal-title":"Cureus"},{"key":"5642_CR24","doi-asserted-by":"publisher","unstructured":"Zurowska A, Peksa R, Bienkowski M et al (2023) Prostate Cancer and Its Mimics-A Pictorial Review. Cancers (Basel) 15. https:\/\/doi.org\/10.3390\/cancers15143682","DOI":"10.3390\/cancers15143682"},{"key":"5642_CR25","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00330-018-5584-y","volume":"29","author":"D Bonekamp","year":"2019","unstructured":"Bonekamp D, Wolf MB, Roethke MC et al (2019) Twelve-month prostate volume reduction after MRI-guided transurethral ultrasound ablation of the prostate. Eur Radiol 29:299\u2013308. https:\/\/doi.org\/10.1007\/s00330-018-5584-y","journal-title":"Eur Radiol"},{"key":"5642_CR26","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1177\/0284185120976931","volume":"62","author":"P Makela","year":"2021","unstructured":"Makela P, Anttinen M, Suomi V et al (2021) Acute and subacute prostate MRI findings after MRI-guided transurethral ultrasound ablation of prostate cancer. Acta Radiol 62:1687\u20131695. https:\/\/doi.org\/10.1177\/0284185120976931","journal-title":"Acta Radiol"},{"key":"5642_CR27","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1080\/02656736.2019.1652773","volume":"36","author":"M Anttinen","year":"2019","unstructured":"Anttinen M, Yli-Pietila E, Suomi V et al (2019) Histopathological evaluation of prostate specimens after thermal ablation may be confounded by the presence of thermally-fixed cells. Int J Hyperthermia 36:915\u2013925. https:\/\/doi.org\/10.1080\/02656736.2019.1652773","journal-title":"Int J Hyperthermia"},{"key":"5642_CR28","doi-asserted-by":"publisher","first-page":"100506","DOI":"10.1016\/j.ejro.2023.100506","volume":"11","author":"P Makela","year":"2023","unstructured":"Makela P, Anttinen M, Wright C, Sainio T, Bostrom PJ, Sequeiros RB (2023) Evolution of non-perfused volume after transurethral ultrasound ablation of prostate: A retrospective 12-month analysis. Eur J Radiol Open 11:100506. https:\/\/doi.org\/10.1016\/j.ejro.2023.100506","journal-title":"Eur J Radiol Open"},{"key":"5642_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/end.2022.0214","volume":"37","author":"MJ Rabinowitz","year":"2023","unstructured":"Rabinowitz MJ, Haney NM, Myers AA, Dora CD, Pavlovich CP (2023) Urinary Outcomes After Magnetic Resonance Imaging-Guided Whole-Gland Transurethral Ultrasound Ablation for Prostate Cancer: Comparison of Suprapubic Tube to Indwelling Urethral Catheter. J Endourol 37:1\u20137. https:\/\/doi.org\/10.1089\/end.2022.0214","journal-title":"J Endourol"}],"container-title":["Abdominal Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05642-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00261-026-05642-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00261-026-05642-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T01:22:45Z","timestamp":1782868965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00261-026-05642-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":29,"alternative-id":["5642"],"URL":"https:\/\/doi.org\/10.1007\/s00261-026-05642-7","relation":{},"ISSN":["2366-0058"],"issn-type":[{"value":"2366-0058","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"10 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Author Masayoshi Miura serves as a medical consultant for Profound Medical Inc. Profound Medical Inc. provided an illustration of the TULSA-PRO system but had no role in the design, conduct, analysis, interpretation, writing, or decision to submit this manuscript. The other authors declare no competing interests relevant to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}